Supportive Care in Cancer

, Volume 19, Issue 6, pp 843–851 | Cite as

Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a US population

  • Amin Haiderali
  • Laura Menditto
  • Margaret GoodEmail author
  • April Teitelbaum
  • Jessica Wegner
Original Article



Chemotherapy-induced nausea and vomiting (CINV) is a debilitating side effect of chemotherapy, but it may be prevented or mitigated with medications. Uncontrolled CINV can lead to reduced quality of life and can result in increased costs (due to health care utilization and missed work). We prospectively assessed the prevalence and burden of CINV in a US population.


Final analysis was performed on 178 patients, beginning chemotherapy during 2007–2008 at oncology specialty settings. Patients kept a diary recording use of antiemetic medications just before the start of chemotherapy and use of antiemetic medications, health care resources, and episodes of nausea and vomiting during the 5 days following. In addition, they completed a Functional Living Index—Emesis (FLIE) questionnaire and a Work Productivity and Assessment Inventory–Nausea and Vomiting assessment, to determine the impact of CINV on daily functioning and on work productivity, respectively. Physicians independently recorded prescribed medications and health care utilization.


Of the patients, 61.2% reported experiencing CINV (34.3% with acute CINV and 58.4% with delayed CINV). Based on the FLIE assessment, 37.2% of all patients reported reduced daily functioning, and of those with poorly managed CINV, about 90% reported a significant impact on daily functioning. Total costs due to CINV were on average $778.58 per patient from the day of administration through the 5 days following the first cycle of chemotherapy; patients with more severe CINV typically had higher costs.


CINV remains a significant problem among US patients, suggesting a need for more effective prophylaxis use in clinical practice.


CINV Functional Living Index—Emesis (FLIE) Medication costs 



The authors would like to thank Jesse Potash and Lee Brekke at i3 Innovus for assistance with the preparation of this manuscript. Financial support for this study was provided by Glaxo Smith Kline.


  1. 1.
    Ballatori E, Roila F, Ruggeri B, Porrozzi S et al (2007) The cost of chemotherapy-induced nausea and vomiting in Italy. Support Care Cancer 15:31–38PubMedCrossRefGoogle Scholar
  2. 2.
    Bloechl-Daum B, Deuson RR, Mavros P, Hansen M et al (2006) Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24:4472–4478PubMedCrossRefGoogle Scholar
  3. 3.
    Cohen L, de Moor CA, Eisenberg P, Ming EE et al (2007) Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 15:497–503PubMedCrossRefGoogle Scholar
  4. 4.
    Geling O, Eichler HG (2005) Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 23:1289–1294PubMedCrossRefGoogle Scholar
  5. 5.
    Grunberg SM (2004) Chemotherapy-induced nausea and vomiting: prevention, detection, and treatment—how are we doing? Support Oncol 2(Suppl 1):1–10Google Scholar
  6. 6.
    Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358:2482–2494PubMedCrossRefGoogle Scholar
  7. 7.
    Ihbe-Heffinger A, Ehlken B, Bernard R, Berger K et al (2004) The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol 15:526–536PubMedCrossRefGoogle Scholar
  8. 8.
    Jordan K, Sippel C, Schmoll HJ (2007) Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. Oncologist 12:1143–1150PubMedCrossRefGoogle Scholar
  9. 9.
    Lachaine J, Yelle L, Kaizer L, Dufour A et al (2005) Chemotherapy-induced emesis: quality of life and economic impact in the context of current practice in Canada. Support Cancer Ther 2:181–187PubMedCrossRefGoogle Scholar
  10. 10.
    Naeim A, Dy SM, Lorenz KA, Sanati H et al (2008) Evidence-based recommendations for cancer nausea and vomiting. J Clin Oncol 26:3903–3910PubMedCrossRefGoogle Scholar
  11. 11.
    Pollera CF, Giannarelli D (1989) Prognostic factors influencing cisplatin-induced emesis. Definition and validation of a predictive logistic model. Cancer 64:1117–1122PubMedCrossRefGoogle Scholar
  12. 12.
    Reilly MC, Zbrozek AS, Dukes EM (1993) The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics 4:353–365PubMedCrossRefGoogle Scholar
  13. 13.
    Tina Shih YC, Xu Y, Elting LS (2007) Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy. Cancer 110:678–685PubMedCrossRefGoogle Scholar
  14. 14.
    Warr DG, Grunberg SM, Gralla RJ, Hesketh PJ et al (2005) The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from 2 randomised, double-blind, placebo controlled trials. Eur J Cancer 41:1278–1285PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Amin Haiderali
    • 1
  • Laura Menditto
    • 2
  • Margaret Good
    • 3
    Email author
  • April Teitelbaum
    • 4
  • Jessica Wegner
    • 5
  1. 1.Global Health Outcomes-Oncology, GlaxoSmithKlineCollegevilleUSA
  2. 2.CVM/Oncology, US Health Outcomes, GlaxoSmithKlinePhiladelphiaUSA
  3. 3.Health Economics & Outcomes, i3 InnovusEden PrairieUSA
  4. 4.Medical & Scientific Affairs, i3 GlobalSan DiegoUSA
  5. 5.Health Economics & Outcomes, i3 InnovusEden PrairieUSA

Personalised recommendations